What is ALGS stock price today?

ALGS (Aligos Therapeutics Inc) stock is trading at $6.00 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ALGS stock going up or down today?

ALGS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ALGS stock now?

The decision to buy ALGS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ALGS a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ALGS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ALGS stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ALGS is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ALGS's P/E ratio?

P/E ratio data for ALGS will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ALGS's market cap?

ALGS (Aligos Therapeutics Inc) has a market capitalization of $0.04 billion, making it a small-cap stock.

What is ALGS's price to book ratio?

ALGS trades at a price-to-book (P/B) ratio of 0.69, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ALGS pay dividends?

ALGS does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ALGS's dividend yield?

ALGS does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ALGS stock a good long-term investment?

ALGS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ALGS's revenue growth rate?

ALGS has shown revenue growth of -0.7% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for ALGS are available on our dashboard with complete income statement analysis.

What are the risks of investing in ALGS?

Key risks for ALGS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ALGS compare to its competitors?

Compare ALGS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ALGS's performance and positioning.

What is ALGS's stock price target for 2026?

Our AI model provides price targets for ALGS based on fundamental analysis: Bull case $7.80 (+30%), Base case $6.90 (+15%), Bear case $5.40 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ALGS?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ALGS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ALGS's next earnings report?

ALGS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ALGS - Aligos Therapeutics Inc

NYSE * Health Care * Biotechnology

$6.00

+$0.03 (+0.50%)

About Aligos Therapeutics Inc

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

ALGS Key Statistics

Market Cap

$36.94M

P/B Ratio

0.69

EPS

$-2.45

Revenue Growth

-0.7%

Employees

How ALGS Compares to Peers

ALGS is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ALGS(This stock)	$36.94M	N/A	-1%	0.0%	-
AMGNAmgen Inc	$182.22B	23.8	0%	0.2%	vs AMGN
GILDGilead Sciences	$159.92B	19.0	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$107.66B	27.6	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$71.96B	16.5	0%	0.3%	vs REGN
BIIBBiogen Inc	$28.53B	20.9	-0%	0.1%	vs BIIB

Aligos Therapeutics Inc Company Information

Headquarters: California; U.S.A
Website: www.aligos.com
Sector: Health Care
Industry: Biotechnology

ALGS - Aligos Therapeutics Inc

About Aligos Therapeutics Inc

ALGS Key Statistics

How ALGS Compares to Peers

Aligos Therapeutics Inc Company Information

ALGS Lician Score

ALGS Financial Snowflake

Upcoming Events for ALGS